Clobetasone butyrate and hydrocortisone butyrate in the treatment of eczema: a double-blind comparison.
Forty patients with symmetrical eczematous lesions on their extremities were treated in a double-blind fashion with 0.05% clobetasone butyrate and 0.1% hydrocortisone butyrate in cream bases. After 2 weeks of treatment, a preference for clobetasone butyrate was observed in 7 cases, for hydrocortisone butyrate in 9 cases and in 24 cases both sides responded equally. The lesions on both sides improved steadily throughout the study in all cases. When completing the trial after 2-weeks' treatment, the clobetasone butyrate-treated lesions had healed in 8 cases and the hydrocortisone butyrate-treated lesions in 10 cases. No local side-effects were observed.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D002990:Clobetasol / Q000009:adverse effects / Q000031:analogs & derivatives; D004311:Double-Blind Method; D004485:Eczema / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006854:Hydrocortisone; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000893:Anti-Inflammatory Agents; C010893:clobetasone butyrate; D001623:Betamethasone; D002990:Clobetasol; D006854:Hydrocortisone